10,118 results match your criteria Acromegaly


Quality of life is significantly impaired in both secretory and non-functioning pituitary adenomas.

Clin Endocrinol (Oxf) 2018 Dec 12. Epub 2018 Dec 12.

Neuroendocrinology Clinic, Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.

Objective: To evaluate the quality of life (QoL) in patients with pituitary adenomas in comparison with healthy Mexican population QoL scores.

Design & Measurements: Cross-sectional study using the short form 36 questionnaire (SF-36) in 175 patients with pituitary adenomas grouped by adenoma subtype and disease activity, and compared them with the healthy Mexican population normative QoL scores.

Patients: 44 patients with non-functioning pituitary adenomas (NFPA), 48 with acromegaly, 53 with prolactinomas and 30 with Cushing disease (CD) were enrolled in this study. Read More

View Article
December 2018

Cystatin C in adipose tissue and stimulation of its production by growth hormone and triiodothyronine in 3T3-L1 cells.

Mol Cell Endocrinol 2018 Dec 10. Epub 2018 Dec 10.

Division of Endocrinology, Diabetes & Clinical Nutrition, University Hospital, Zurich, Switzerland.

Cystatin C (CysC) is a marker for estimation of glomerular filtration rate (GFR). CysC levels may depend not only on clearance/GFR but possibly also on changes in production. Our studies on tissue distribution of CysC protein in mice showed that adipose tissue expresses significant amounts of CysC, suggesting that adipocytes could contribute to circulating CysC levels in vivo. Read More

View Article
December 2018

Hypertension is Common in Patients with Newly Diagnosed Acromegaly and is Independently Associated with Renal Resistive Index.

High Blood Press Cardiovasc Prev 2018 Dec 7. Epub 2018 Dec 7.

Department of Radiology, University of Health Sciences-Adana Health Practice and Research Center, Dr. Mithat Özsan Bulvarı Kışla Mah, 4522 Sok, No: 1 Yüreğir, Adana, Turkey.

Introduction: There are conflicting results regarding the frequency of hypertension (HT) and values of related parameters in patients with acromegaly.

Aim: We aimed to determine the frequency of HT and values of its associated parameters in patients with acromegaly.

Methods: 57 patients with newly diagnosed acromegaly were included in this study. Read More

View Article
December 2018

Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study.

Cancer Chemother Pharmacol 2018 Dec 8. Epub 2018 Dec 8.

Endocrinology, DiMI and CEBR, University of Genoa, Genoa, Italy.

Purpose: Octreotide SC depot is a novel, ready-to-use formulation administered via a thin needle. In a phase 1 study in healthy volunteers, this formulation provided higher bioavailability of octreotide with faster onset and stronger suppression of IGF-1 in healthy volunteers versus long-acting intramuscular (IM) octreotide. This phase 2 study evaluated the pharmacokinetics, efficacy, and safety of octreotide SC depot in patients with acromegaly and functioning NETs, previously treated with octreotide IM. Read More

View Article
December 2018

[Spontaneous remission of acromegaly and Cushing's disease in older patients. Report of two cases].

Rev Med Chil 2018 Jul;146(7):933-937

Departamento de Neurología y Neurocirugía, Hospital Clínico de la Universidad de Chile, Santiago, Chile.

Pituitary diseases such as acromegaly and Cushing's disease require surgical or medical therapy. In some functioning pituitary tumors, a spontaneous remission of hormonal hypersecretion is observed, mainly associated to apoplexy or pituitary infarction. We report the evolution of two female patients older than 70 years at the time of diagnosis, with multiple comorbidities. Read More

View Article
July 2018
1 Read

Silent somatotropinomas.

Minerva Endocrinol 2018 Dec 7. Epub 2018 Dec 7.

Pathology Department, Hospital General Universitario de Alicante, Alicante, Spain.

Silent somatotroph pituitary neuroendocrine tumors (or silent growth hormone pituitary neuroendocrine tumors, SGH-PitNET) are neoplasias with positive immunostaining for growth hormone (GH), in patients with no signs and symptoms of acromegaly nor biochemical evidence of GH hypersecretion. From a clinical stand-point they are considered and managed as non-functioning pituitary tumors, since they usually come to evidence due to mass-effects (headache, visual impairment, hypopituitarism) or as asymptomatic pituitary incidentalomas. SGH-PitNET have deserved little attention in the medical literature, and no specific guidelines exist regarding their management. Read More

View Article
December 2018

Precision medicine in the treatment of acromegaly.

Minerva Endocrinol 2018 Dec 7. Epub 2018 Dec 7.

Endocrinology Service, Hospital de la Princesa, Madrid, Spain.

Acromegaly is a chronic disorder usually diagnosed late in the disease evolution, leading to substantial morbidity and mortality related to this long period of undiagnosed state as well as the difficulty in achieving normalization of GH hypersecretion and controlling tumour mass. First generation somatostatin analogues (SSA) are accepted as the first-line medical therapy or as second-line therapy in patients undergoing unsuccessful surgery. However, because a high percentage of patients experience SSA treatment failure, the inclusion of biomarkers associated with a successful or non-successful response to these drug ( as well as to all classes of medical therapy) is necessary to better guide the choice of treatment, potentially allowing for a quicker achievement of disease control. Read More

View Article
December 2018

Pathological markers of somatotroph pituitary neuroendocrine tumors (PitNET)s predicting the response to medical treatment.

Minerva Endocrinol 2018 Dec 7. Epub 2018 Dec 7.

Lyon 1, Université de Lyon, Lyon, France -

Acromegaly is mainly due to the somatotroph pituitary neuroendocrine tumors (PitNET)s. These have been subtyped into densely granulated (DG) and sparsely granulated (SG) tumors, which differ in clinical, histological and biological characteristics and in response to somatostatin analogs (SA)s. The variable remission rate after surgical resection, as first line treatment, has increased interest in identifying pathological markers to better predict the response to medical treatment. Read More

View Article
December 2018

[Acromegaly].

Ugeskr Laeger 2018 Dec;180(49)

Acromegaly is a rare and disabling disease with a plethora of symptoms and signs attributed to sustained elevations and actions of growth hormone and insulin-like growth factor 1. Acromegaly is characterised by excessive somatic growth and multiple comorbidities in addition to occasional compression of the optic nerve and hypopituitarism due to the underlying adenoma. The course of the disease is insidious, and a diagnostic delay of 5-10 years is typical, and this pre-diagnostic period is also associated with increased morbidity. Read More

View Article
December 2018
1 Read

Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI.

Eur Radiol 2018 Nov 30. Epub 2018 Nov 30.

Department of Radiology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Objective: To investigate the value of machine learning (ML)-based high-dimensional quantitative texture analysis (qTA) on T2-weighted magnetic resonance imaging (MRI) in predicting response to somatostatin analogues (SA) in acromegaly patients with growth hormone (GH)-secreting pituitary macroadenoma, and to compare the qTA with quantitative and qualitative T2-weighted relative signal intensity (rSI) and immunohistochemical evaluation.

Methods: Forty-seven patients (24 responsive; 23 resistant patients to SA) were eligible for this retrospective study. Coronal T2-weighted images were used for qTA and rSI evaluation. Read More

View Article
November 2018
1 Read

Role of stereotactic radiosurgery in the treatment of acromegaly.

J Pak Med Assoc 2018 Dec;68(12):1843-1845

Department of Surgery, Section of Neurosurgery, Aga Khan University Hospital, Karachi. Pakistan.

Acromegaly is a rare, indolent disease due to overproduction of growth hormone. Surgery is identified as primary treatment, but has its limitation, thus frequently requiring alternate treatment options as adjunct to surgery. Stereotactic radiosurgery (SRS) has been used as adjuvant and alternate therapy in patients with inoperable or residual disease; or those not fit for surgery. Read More

View Article
December 2018
5 Reads

Radiotherapy and pasireotide treatment of a growth hormone producing pituitary tumor in a diabetic dog.

Can Vet J 2018 Oct;59(10):1089-1093

Southfields Veterinary Specialists, formerly VRCC, Laindon, United Kingdom (Zublena, Tamborini, North, Lobacz); SeersCroft, North Norsham, United Kingdom (Andrew); University Veterinary Hospital, Dublin, Ireland (Mooney); Department of Clinical Science and Services, The Royal Veterinary College, Herts, United Kingdom (Woolhead, Covey, Church, Niessen); Novartis Institutes for BioMedical Research, Oncology Research, Novartis Pharma AG, Basel, Switzerland (Schmid).

An 8-year-old castrated male border terrier dog was diagnosed with acromegaly resulting from a growth hormone secreting pituitary tumor. Sixteen daily fractions of radiation therapy were delivered followed, approximately 1 year later, by administration of pasireotide. The aforementioned treatment was considered effective and should be further evaluated in similar cases. Read More

View Article
October 2018
2 Reads

Growth Hormone's Links to Cancer.

Endocr Rev 2018 Nov 30. Epub 2018 Nov 30.

Department of Pediatrics, Endocrine Division (SEMPR), University Hospital, Federal University of Parana, Curitiba, Brazil.

Several components of the GH axis are involved in tumor progression and GH-induced intracellular signaling has been strongly associated with breast cancer susceptibility in genome-wide association studies. In the general population, high IGF-I levels and low IGFBP-3 levels within the normal range are associated with the development of common malignancies, and components of the GH-IGF signaling system exhibit correlations with clinical, histopathological and therapeutic parameters in cancer patients. Despite promising findings in preclinical studies, anti-cancer therapies targeting the GH-IGF signaling system have led to disappointing results in clinical trials. Read More

View Article
November 2018
2 Reads

Surgical results and predictors of initial and delayed remission for growth hormone-secreting pituitary adenomas using the 2010 consensus criteria in 162 patients from a single center.

World Neurosurg 2018 Nov 27. Epub 2018 Nov 27.

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China; Shanghai Pituitary Tumor Center, Shanghai 200040, China. Electronic address:

Background: Factors associated with initial and delayed remission after growth hormone (GH)-secreting pituitary adenoma excision have not been completely elucidated.

Methods: We recruited 185 consecutive patients treated for GH-secreting pituitary adenomas between January 2013 and December 2014 and assessed their tumor characteristics and surgical outcomes. The criteria for initial or delayed remission (based on the 2010 consensus criteria) were normalized insulin-like growth factor 1 (IGF-1) levels, GH levels below 0. Read More

View Article
November 2018
1 Read

GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly.

J Endocrinol Invest 2018 Nov 28. Epub 2018 Nov 28.

Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy.

Purpose: Biomarkers of clinical and therapeutic outcome in acromegaly are needed. Polymorphisms or epigenetic changes of detoxification genes, such as those coding for the aryl hydrocarbon receptor (AHR) and the glutathione-S-transferase-P1 (GSTP1), could have a role in GH secreting pituitary tumors' pathophysiology and clinical expression. In this study, we assessed the contribution of GSTP1 gene promoter methylation status, per se or in combination with the occurrence of the AHR gene rs2066853 variant, on clinical features and response to somatostatin analogs (SSA) treatment in acromegaly patients. Read More

View Article
November 2018
1 Read

Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.

Pituitary 2018 Nov 27. Epub 2018 Nov 27.

Endocrinology Unit, Department of Internal Medicine, Policlinico San Martino, 16132, Genoa, Italy.

Background: Pasireotide is a second-generation somatostatin (SRIF) receptor ligand (SRL), approved for medical treatment of acromegaly and Cushing's disease (CD). The molecule is a stable cyclohexapeptide synthetized based on SRIF structure. Differently from first-generation SRLs (e. Read More

View Article
November 2018
1 Read

Sleep apnea and cardiovascular complications of the acromegaly. Response to the medical treatment.

Minerva Endocrinol 2018 Nov 26. Epub 2018 Nov 26.

Cardiology Department, University General Hospital of Alicante, Alicante, Spain -

Acromegaly is a rare disease characterized by high levels of growth hormone (GH) and insulin- like growth factor 1 (IGF-1). The excess of GH leads to the development of different manifestations in different organs, from subtle signs in the bones and soft tissues to the development of respiratory and cardiac insufficiency. In the cardiovascular system, the GH/IGF-1 axis exerts its influence on three major aspects: myocyte growth and structure, cardiac contractility and vascular function. Read More

View Article
November 2018
15 Reads

Clinical characteristics of acromegalic patients with paradoxical growth hormone response to oral glucose load.

J Clin Endocrinol Metab 2018 Nov 23. Epub 2018 Nov 23.

Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.

Context: Paradoxical GH response to oral glucose (OG) is often found in acromegaly. However, the clinical characteristics of acromegalic patients with paradoxical GH response to OG (OG responders) remains unclear.

Objective: The aim of the present study was to define the clinical characteristics of OG responders with acromegaly. Read More

View Article
November 2018
7 Reads

Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy.

Endocrine 2018 Nov 24. Epub 2018 Nov 24.

Endocrine Care, Pfizer Inc, New York, NY, USA.

Purpose: To explore the effects of pegvisomant (PEGV) on glucose metabolism in patients with acromegaly within ACROSTUDY, an international, observational, prospective safety surveillance study.

Methods: Patients were retrospectively divided into two cohorts, with (DM group) or without diabetes mellitus (no-DM). Parameters of glucose metabolism and IGF-I values were analyzed yearly both cross-sectionally for 4 years (yrs) and longitudinally at 1 and 4-5 yrs of PEGV treatment. Read More

View Article
November 2018
4 Reads

Identification of the risk factors of the thyroid cancer by using logit model in Lahore.

Pak J Pharm Sci 2018 Nov;31(6):2391-2396

Government College University, Lahore, Pakistan.

Thyroid Cancer is a disease, which becomes a cause of death in developing countries. The aim of this study is to investigate all the possible risk factors of thyroid cancer in Pakistan. This study was consisting of 320 individuals, including 160 cases and 160 controls. Read More

View Article
November 2018
1 Read

Super Giant GH-secreting pituitary adenoma in a young woman: from the ventricles to the nose.

World Neurosurg 2018 Nov 22. Epub 2018 Nov 22.

Section of Neurosurgery, Division of Neuroscience, University of Turin, Corso Bramante 88/90, 10126 Turin, Italy.

Background: Giant pituitary adenomas (GPA) are rare tumors that can have a devastating impact on a patient's life. They require a well studied therapeutic approach that often combines different strategies.

Methods: A 29-year-old woman was diagnosed with the largest GH-secreting pituitary adenoma reported in literature, to the best of the authors knowledge. Read More

View Article
November 2018
2 Reads

Long-term management and postmortem examination in a diabetic cat with acromegaly treated with two courses of radiation therapy.

J Vet Med Sci 2018 Nov 16. Epub 2018 Nov 16.

School of Veterinary Nursing & Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University.

A 12-year-old, castrated male cat with diabetes mellitus was diagnosed with acromegaly and examined with magnetic resonance imaging (enlarged pituitary gland, 8 mm); serum hormone concentrations were measured. After the first course of radiation therapy (4 Gy, 12 fractions), insulin administration was not required from day 420 after diagnosis. Enlarged pituitary tumor (8 mm) recurred, and insulin dosage amount of the cat was increased on day 1,065. Read More

View Article
November 2018
3 Reads

Long-Term Efficacy and Tolerability of Gamma Knife Radiosurgery for Growth Hormone-Secreting Adenoma: A Retrospective Multicenter Study (MERGE-001).

World Neurosurg 2018 Nov 15. Epub 2018 Nov 15.

Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

Objective: Little is known about the long-term efficacy, prognostic factors, and tolerability of gamma knife radiosurgery (GKS) for acromegaly. The aim of this study was to investigate long-term hormonal effects, prognostic factors, and tolerability of GKS in patients with growth hormone-secreting adenoma.

Methods: A retrospective multicenter study over 25 years with a median follow-up of 85. Read More

View Article
November 2018
3 Reads
2.417 Impact Factor

Pseudoacromegaly.

Front Neuroendocrinol 2018 Nov 15. Epub 2018 Nov 15.

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. Electronic address:

Individuals with acromegaloid physical appearance or tall stature may be referred to endocrinologists to exclude growth hormone (GH) excess. While some of these subjects could be healthy individuals with normal variants of growth or physical traits, others will have acromegaly or pituitary gigantism, which are, in general, straightforward diagnoses upon assessment of the GH/IGF-1 axis. However, some patients with physical features resembling acromegaly - usually affecting the face and extremities -, or gigantism - accelerated growth/tall stature - will have no abnormalities in the GH axis. Read More

View Article
November 2018
5 Reads

Delayed Remission of Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Adenectomy.

World Neurosurg 2018 Nov 14. Epub 2018 Nov 14.

Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; China Pituitary Disease Registry Center, Chinese Pituitary Adenoma Cooperative Group, Beijing, China. Electronic address:

Objective: To investigate the clinical characteristics of delayed remission (DR) of growth hormone (GH)-secreting pituitary adenoma after transsphenoidal adenectomy and inform follow-up treatments.

Methods: We retrospectively reviewed 87 patients who had undergone transsphenoidal surgery for acromegaly. Demographic, radiological, and endocrinological data were reviewed before, immediately after, 3 months after, and in the long term (2. Read More

View Article
November 2018
3 Reads

Quality of Life Changes Before and After Transsphenoidal Surgery for Sellar and Parasellar Lesions.

World Neurosurg 2018 Nov 14. Epub 2018 Nov 14.

Department of Neurosurgery, Graduate School of Medicine, Nagoya University, Nagoya, Aichi, Japan.

Objective: Although reports regarding the relationship between surgical complications and quality of life (QOL) exist, a general consensus regarding this issue is lacking. The aim of this study was to evaluate QOL after endoscopic transsphenoidal approach.

Methods: We assessed patients with sellar or parasellar lesions that were removed with endoscopic transsphenoidal approach or extended endoscopic transsphenoidal approach between January 2010 and December 2016. Read More

View Article
November 2018

Evaluation of the natural course of thyroid nodules in patients with acromegaly.

Pituitary 2018 Nov 14. Epub 2018 Nov 14.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Capa, 34090, Istanbul, Turkey.

Purpose: To investigate the nodular thyroid disease (NTD) and the natural course of thyroid nodules in patients with acromegaly.

Methods: 138 patients with acromegaly (73 F/65 M), whose initial thyroid ultrasonography performed in our university hospital, were included in this study. The frequencies of NTD, papillary thyroid cancer (PTC) and associated factors on nodule formation were investigated at initial assessment. Read More

View Article
November 2018
16 Reads

Carney Complex.

Exp Clin Endocrinol Diabetes 2018 Nov 14. Epub 2018 Nov 14.

Section on Endocrinology and Genetics & Endocrinology Inter-institute Training Program, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.

Carney complex is a rare, autosomal dominant, multiple endocrine neoplasia and lentiginosis syndrome, caused in most patients by defects in the gene, which encodes the regulatory subunit type 1α of protein kinase A. Inactivating defects of lead to aberrant cyclic-AMP-protein kinase A signaling. Patients may develop multiple skin abnormalities and a variety of endocrine and non-endocrine tumors. Read More

View Article
November 2018
4 Reads

[Acromegaly and symptoms of the motor apparatus].

Ugeskr Laeger 2018 Nov;180(46)

In this case report, a 72-year-old woman presented with symptoms attributed to arthritis, and MRI indicated sacroiliitis. However, the patient also experienced enlargement of hands and feet in addition to sweating and snoring, which in combination with coarse facial features suggested acromegaly. This diagnosis was biochemically confirmed, and MRI revealed a pituitary adenoma, which was successfully removed by transsphenoidal surgery. Read More

View Article
November 2018
1 Read

Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism?

Endocrine 2018 Nov 10. Epub 2018 Nov 10.

Division of Endocrinology, Diabetes and Metabolism Johns Hopkins University, Baltimore, MD, 21287, USA.

Purpose: The growth hormone (GH) nadir during oral glucose tolerance test (OGTT) is the gold standard diagnostic test for acromegaly. The utility of OGTT-GH suppression test in patients with abnormal glucose metabolism (AGM) has not been well established. In this study, we compared the GH nadir during OGTT in patients evaluated for acromegaly in the presence and absence of AGM. Read More

View Article
November 2018
7 Reads

Association of Acromegaly and Central Sleep Apnea Syndrome.

Turk Thorac J 2017 Nov 29:1-3. Epub 2017 Nov 29.

Department of Radiology, Gaziosmanpaşa University School of Medicine, Tokat, Turkey.

Acromegaly is usually characterized by the excessive secretion of growth hormone (GH) after the closure of epiphyseal plaques, resulting from functional pituitary adenomas. The most common manifestations of acromegaly are acral and soft tissue overgrowth, diabetes mellitus, hypertension, and heart and respiratory failure. In patients, obstruction of the upper airway may develop due to enlargement of the tongue and thickening of the tissues of the larynx; consequently, obstructive sleep apnea syndrome (OSAS) occurs commonly in acromegaly. Read More

View Article
November 2017
12 Reads

Postoperative use of somatostatin analogs and mortality in patients with acromegaly.

Eur J Endocrinol 2018 Oct 1. Epub 2018 Oct 1.

A van Beek, Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

Objective: To assess the effect of somatostatin analogs (SSA) on mortality in relation to disease control of acromegaly after pituitary surgery.

Design: A retrospective study in two large tertiary referral centers in The Netherlands.

Methods: 319 patients with acromegaly in whom pituitary surgery was performed as primary therapy between January 1980 and July 2017 were included. Read More

View Article
October 2018
9 Reads

Growth hormone controls lipolysis by regulation of FSP27 expression.

J Endocrinol 2018 Dec;239(3):289-301

Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA.

Growth hormone (GH) has long been known to stimulate lipolysis and insulin resistance; however, the molecular mechanisms underlying these effects are unknown. In the present study, we demonstrate that GH acutely induces lipolysis in cultured adipocytes. This effect is secondary to the reduced expression of a negative regulator of lipolysis, fat-specific protein 27 (FSP27; aka Cidec) at both the mRNA and protein levels. Read More

View Article
December 2018
3 Reads
3.720 Impact Factor

Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Endocrine 2018 Nov 5. Epub 2018 Nov 5.

Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, F-94275, Le Kremlin Bicêtre, France.

Context: Untreated acromegaly is associated with increased morbidity and mortality due to malignant, cardiovascular, and cerebrovascular disorders. Effective treatment of acromegaly reduces excess mortality, but its impact on cardiovascular risk factors and metabolic parameters are poorly documented.

Aim: We analyzed changes in cardiovascular risk factors and metabolic parameters in patients receiving various treatment modalities. Read More

View Article
November 2018
4 Reads

Ca2+ Channels in Anterior Pituitary Somatotrophs: A Therapeutic Perspective.

Endocrinology 2018 Dec;159(12):4043-4055

Department of Medical Neurobiology, Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University Faculty of Medicine, Jerusalem, Israel.

Ca2+ influx through voltage-gated Ca2+ channels (VGCCs) plays a key role in GH secretion. In this review, we summarize the current state of knowledge regarding the physiology and molecular machinery of VGCCs in pituitary somatotrophs. We next discuss the possible involvement of Ca2+ channelopathies in pituitary disease and the potential use of Ca2+ channel blockers to treat pituitary disease. Read More

View Article
December 2018
3 Reads

Growth hormone and chronic kidney disease.

Curr Opin Nephrol Hypertens 2019 Jan;28(1):10-15

Departments of Pediatrics and Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA.

Purpose Of Review: Elevated circulating levels of growth hormone (GH) and/or increased expression of the GH receptor in the kidney are associated with the development of nephropathy in type1 diabetes and acromegaly. Conditions of GH excess are characterized by hyperfiltration, glomerular hypertrophy, glomerulosclerosis and albuminuria, whereas states of decreased GH secretion or action are protected against glomerulopathy. The direct role of GH's action on glomerular cells, particularly podocytes, has been the focus of recent studies. Read More

View Article
January 2019
10 Reads

Gigantism in a McCune-Albright's syndrome with calcified GH-releasing pituitary adenoma: Case report and literature review.

Int J Surg Case Rep 2018 Oct 23;53:61-65. Epub 2018 Oct 23.

Neurosurgery Department, National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez", Mexico City, Mexico.

Background: McCune-Albright's syndrome (MAS) is a rare disorder that is characterized by café-au-lait macules, fibrous dysplasia of the skull and endocrinopathies like excessive secretion of growth hormone by a hyper-functional pituitary adenoma (PA).

Case: We describe the case of a 43-year-old male with history of Gigantism in 1990 secondary to a GH-secreting pituitary macroadenoma that was treated via microscopic transsphenoidal surgery at that time. He was reported as asymptomatic for 26 years until he developed headache and right temporal hemianopia with left amaurosis. Read More

View Article
October 2018
11 Reads

Economics of Acromegaly Treatment in Brazil: A Budget Impact Analysis of Pituitary Surgery Compared with Long-Term Octreotide LAR.

Pharmacoecon Open 2018 Nov 2. Epub 2018 Nov 2.

Faculty of Health Sciences, University of Brasilia, Brasília, Brazil.

Background: Acromegaly is a rare, chronic and debilitating disease whose treatment places a high burden on health systems. In the reality of the Brazilian public health network, many patients are kept on drug treatment because of barriers to access to surgery.

Objective: The aim of this study was to estimate the costs and budget impact of routine transsphenoidal endoscopic surgery in relation to those of long-term drug treatment with octreotide long-acting release (LAR) from a cohort of patients followed at the referral medical centre for acromegaly treatment in the Federal District, Brazil. Read More

View Article
November 2018
1 Read

Correction to: Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study.

Endocrine 2018 Oct 31. Epub 2018 Oct 31.

Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Centre de Référence des Maladies Rares de l'Hypophyse HYPO, F94275, Le Kremlin-Bicêtre, France.

The original version of this article unfortunately contained a mistake in corresponding author name as Philippe Chanson in the affiliation section. Read More

View Article
October 2018
2 Reads

Standardization of Growth Hormone and Insulin-like Growth Factor-I Measurement.

Pediatr Endocrinol Rev 2018 Sep;16(Suppl 1):28-32

Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan, E-mail:

Determination of serum levels of GH and IGF-I is crucial for the diagnosis and treatment of GH deficiency and disorders related to GH excess such as acromegaly and pituitary gigantism. However, significant discrepancies in measured GH values among the methods were observed around the world. In Japan, the Study Committee for GH and Its Related Factors of The Foundation for Growth Science standardized GH values measured with various commercially available GH assay kits by creating formulas to adjust them to their averages. Read More

View Article
September 2018
1 Read

Growth Hormone Discovery and Structure.

Pediatr Endocrinol Rev 2018 Sep;16(Suppl 1):2-10

Heritage College of Osteopathic Medicine, Department of Biomedical Sciences, Ohio University, Athens, Ohio, USA, E-mail:

The purpose of this review is to describe and document the discovery of growth hormone (GH) and various activities associated with it. Crucial to this discourse will be a chronicle of results related to the structure of GH. Many individuals were instrumental in the early and current work. Read More

View Article
September 2018
1 Read

Hypermethylator phenotype and ectopic GIP receptor in GNAS mutation-negative somatotropinomas.

J Clin Endocrinol Metab 2018 Oct 29. Epub 2018 Oct 29.

Institut National de la Santé et de la Recherche Médicale (Inserm) U1185, Le Kremlin Bicêtre, France.

Context: Besides GNAS gene mutations, the molecular pathogenesis of somatotroph adenomas responsible for gigantism and acromegaly remains elusive.

Objective: To investigate alternative driver events in somatotroph tumorigenesis, focusing on a subgroup of acromegalic patients with a paradoxical increase in GH secretion after oral glucose, resulting from ectopic glucose-dependent insulinotropic polypeptide receptor (GIPR) expression in their somatotropinomas.

Design, Patients And Setting: We performed combined molecular analyses including array-CGH, RNA/ DNA FISH, and high-resolution DNA methylation analysis on 41 somatotropinoma samples from 38 patients with acromegaly and 3 sporadic giants. Read More

View Article
October 2018
5 Reads

Growth hormone-secreting pituitary macroadenoma presenting concurrently with non-Hodgkin's lymphoma and responding to doxorubicin treatment: case report and review of the literature.

Acta Neurochir (Wien) 2018 Dec 29;160(12):2363-2366. Epub 2018 Oct 29.

John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA, 90404, USA.

We present a case report of a patient who presented with nausea and vomiting, as well as acromegalic features. Following testing, a pituitary adenoma and mediastinal non-Hodgkin's lymphoma were diagnosed. Following two cycles of R-CHOP chemotherapy, imaging showed significant decrease in size of the sellar tumor. Read More

View Article
December 2018
5 Reads

Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly.

Pituitary 2018 Dec;21(6):615-623

Aix-Marseille Université, Institut National de la Santé et de la Recherche Médicale (INSERM), U1251, Marseille Medical Genetics (MMG), Marseille, France.

Purpose: To determine whether pre-surgical medical treatment (PSMT) using long-acting Somatostatin analogues in acromegaly may improve long-term surgical outcome and to determine decision making criteria.

Methods: This retrospective study included 110 consecutive patients newly diagnosed with acromegaly, who underwent surgery in a reference center (Marseille, France). The mean long-term follow-up period was 51. Read More

View Article
December 2018
5 Reads

Updates in Diagnosis and Treatment of Acromegaly.

Eur Endocrinol 2018 Sep 10;14(2):57-61. Epub 2018 Sep 10.

Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition.

Acromegaly is a rare disease, caused largely by a growth hormone (GH) pituitary adenoma. Incidence is higher than previously thought. Due to increased morbidity and mortality, if not appropriately treated, early diagnosis efforts are essential. Read More

View Article
September 2018
1 Read

Repurposing of Bromocriptine for Cancer Therapy.

Front Pharmacol 2018 8;9:1030. Epub 2018 Oct 8.

Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany.

Bromocriptine is an ergot alkaloid and dopamine D receptor agonist used to treat Parkinson's disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus. The drug is also active against pituitary hormone-dependent tumors (prolactinomas and growth-hormone producing adenomas). We investigated, whether bromocriptine also inhibits hormone-independent and multidrug-resistant (MDR) tumors. Read More

View Article
October 2018
10 Reads

Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression.

J Clin Endocrinol Metab 2018 Oct 19. Epub 2018 Oct 19.

Department of Medicine, Endocrinology section, Pituitary Center Rotterdam, Erasmus University Medical Center, Rotterdam, the Netherlands.

Background: The response to first-generation somatostatin receptor ligands (SRLs) treatment in acromegaly correlates with expression of somatostatin receptor subtype 2 (SSTR2). However, pasireotide shows the highest binding affinity for SSTR5. It has been suggested that in acromegaly SSTR5 expression is better at predicting the response to pasireotide LAR (PAS-LAR) treatment than SSTR2 expression. Read More

View Article
October 2018
6 Reads

A designed cell-penetrating human SOCS2 protein suppresses GH-dependent cancer cell proliferation.

Biosci Biotechnol Biochem 2018 Oct 22:1-9. Epub 2018 Oct 22.

a Department of Applied Life Sciences, Graduate School of Bioresource Sciences , Nihon University , Kanagawa , Japan.

Suppressor of cytokine signaling (SOCS) 2, a negative regulator of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), which is associated with acromegaly and cancers, is a promising candidate molecule for treating various diseases. To facilitate its use in protein therapy, we designed and constructed a human SOCS2 protein containing a membrane-permeable peptide sequence and expressed it in an Escherichia coli system. The partially purified recombinant protein was effectively delivered into several cancer cell lines and inhibited cell growth. Read More

View Article
October 2018
1 Read